LC0406S

HepG2+Insulin Cytosol

Cytosolic lysate boiled in SDS-PAGE sample buffer prepared from HepG2 cells that were cultivated to 70-90% confluency and deprived of serum for 18-20 hours and then treated with 5 µg/ml insulin for 15 minutes prior to harvesting

Address: 8755 Ash Street, Suite 1
Vancouver, British Columbia,
Canada V6P 6T3

Email: info@kinexus.ca
Phone: 604-323-2547

Production

Product Name Long:	Human hepatic carcinoma HepG2 cells - Insulin-treated - Cytosolic lysate
Production Method:	HepG2 cells were cultivated to 70-90% confluency and deprived of serum for 18-20 hours and then treated with 5 µg/ml insulin for 15 minutes prior to harvesting. Lysates were prepared from scrapped cells that were homogenized by sonication in buffer formulated with 60 mM β-glycerophosphate, pH 7.2, 20 mM MOPS, 20 mM sodium pyrophosphate, 30 mM sodium fluoride, 5 mM EDTA, 3 mM benzamidine, 2 mM EGTA, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonylfluoride, 1 mM dithiothreitol, 10 µM leupeptin, and 5 µM pepstatin A. Cytosolic lysates were prepared following sonication and 30 min ultracentrifugation at 100,000 rpm. Lysates were further diluted in SDS-PAGE sample buffer at a final concentration of 2 mg/ml.
Amount:	200 µg
Protein Concentration:	2 mg/ml
Storage Stability:	1 year at -70°C

Applications

Lysate Use Description:	For testing antibodies by immunoblotting.